Back to CITADEL ADVISORS LLC CITADEL ADVISORS LLC

ARQTARQT
Showing 8 of 26 quarters

Position history for CITADEL ADVISORS LLCCITADEL ADVISORS LLC's holdings in ARCUTIS BIOTHERAPEUTICS INC

CITADEL ADVISORS LLC holds 1.2M shares of ARQT (ARCUTIS BIOTHERAPEUTICS INC), worth $30.4M as of 2026-Q2. The position was increased (+7333.1% shares). ARQT represents 0.0% of CITADEL ADVISORS LLC's portfolio.

Current Value

$30.4M

Current Shares

1.2M

Total Value Change

+$2.2M

Total Shares Change

-1.9M

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
1.2M
+7333.1%
$30.4M0.0%$26.22
46
2026-Q1
Decreased
15,606
-89.9%
$367,6770.0%$23.56
0
2025-Q4
Decreased
155,158
-12.5%
$4.5M0.0%$29.04
0
2025-Q3
Increased
177,268
+21.8%
$3.3M0.0%$18.85
32
2025-Q2
Decreased
145,493
-53.1%
$2M0.0%$14.02
0
2025-Q1
Increased
310,075
+247.7%
$4.8M0.0%$15.64
43
2024-Q4
Decreased
89,168
-97.1%
$1.2M0.0%$13.93
0
2024-Q3
Increased
3M
+3.4%
$28.2M0.0%$9.30
30

Other major holders of ARQT: BlackRock, Inc., JENNISON ASSOCIATES LLC, VANGUARD GROUP INC

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used